Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products.

Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products. J Manag Care Spec Pharm. 2020 Apr; 26(4):504-512.

View in: PubMed

subject areas

Adolescent
Child
Cost Savings
Drug Administration Schedule
Drug Costs
Factor VIII
Half-Life
Hemophilia A
Hemorrhage
Humans
Male
Recombinant Proteins
Retrospective Studies
Time Factors
Treatment Outcome
United States

authors with profiles

Mindy Simpson